dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
Published 6 years ago • 616 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
1:56
dr. brahmer discusses the future of antibodies for lung cancer
-
1:41
dr. brahmer discusses second-line pembrolizumab in nsclc
-
1:29
dr. brahmer on managing immune-related aes in lung cancer
-
1:25
dr. brahmer on chemoimmunotherapy in patients with nsclc
-
0:31
copy of dr. brahmer on the role of immunotherapy in metastatic nsclc
-
1:14
dr. brahmer on immunotherapy in stage iv nsclc
-
1:15
dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc
-
1:23
dr. brahmer on biomarkers for immune response in nsclc
-
0:19
copy of dr. brahmer on immunotherapy in stage iv nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
1:32
dr. brahmer on the benefit of immunotherapy in metastatic nsclc
-
1:54
dr. wakelee on fda approval of frontline pembrolizumab in nsclc
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
1:50
dr. levy discusses pembrolizumab in nsclc
-
3:54
pembrolizumab: new drug for advanced lung cancer
-
1:49
dr. herbst on the impact of frontline immunotherapy in lung cancer
-
0:58
dr. julie r. brahmer on immunotherapy development in lung cancer
-
2:03
dr. brahmer discusses tumor vaccines for lung cancer
-
1:18
dr. brahmer on 5-year follow-up data for nivolumab in nsclc